Procalcitonin Aided Antimicrobial Therapy vs Standard of Care
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAzienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
About this trial
Antibiotic resistance is driven by overuse, especially for viral respiratory infections. Procalcitonin (PCT), a biomarker for bacterial infections, helps guide antibiotic therapy more precisely, reducing unnecessary use and improving outcomes. Studies, including large trials and economic models across several countries, show PCT-guided treatment lowers mortality, antibiotic exposure, therapy duration and related complications, potentially reducing hospital costs despite initial testing expenses.
Eligibility criteria
Qualifiers
age ≥18 years;
clinical and instrumental diagnosis of LRTI consistent with bacterial origin and requiring antimicrobial treatment;
patient hospitalized in Internal Medicine, Geriatrics, Infectious Disease unit, Pneumology, Semi Intensive Care unit, ICU, Emergency Medicine;
informed consent provided by the patient.
Disqualifiers
age < 18 years;
lack of informed consent;
severe immunosuppression (other than related to corticosteroid use);
concomitant diagnosis of other infections requiring long term antimicrobial therapy (i.e. endocarditis, osteomyelitis)
Trial design
Treatments tested in this trial
- Procalcitonin-guided antibiotic management
- Standard of care
Treatment groups
108 Participants
are divided into 2 treatment groupsSponsors and collaborators
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Lead sponsor
Thermo Fisher Scientific FS
Collaborator
Source ClinicalTrials.gov